Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Research Article Volume 7 Issue 3

Pulse Immunomodulatory Mesotherapy of Psoriasis

Zavadsky VN*

Department of Skin and Venereal Diseases of the Yaroslavl State Medical Academy, Russia

*Corresponding Author: Zavadsky VN, Department of Skin and Venereal Diseases of the Yaroslavl State Medical Academy, Russia.

Received: January 18, 2023; Published: February 14, 2023


Pulse immunomodulatory mesotherapy (PIMT) for mild and moderate forms of psoriasis is described. A suspension of a prolonged-acting glucocorticoid in a mini-dose - betamethasone 7 mg (or triamcinolone 40 mg) - is diluted with a saline solution of sodium chloride, 10-15 mg of methotrexate is added as an injection solution, and this mixture of drugs is injected intradermally into the lesions 1 time per month. The effectiveness of PIMT in psoriasis, which is an immune-dependent chronic disease, has been shown. PIMT is a convenient alternative to local corticosteroids - for the treatment of adults, adolescents and partly children. With a mild course of psoriasis, PIMT has a sufficient and pathogenetic effect. Advantages of PIMT: treatment is carried out no more than 1 time per month, simultaneously; the effect is manifested from the first days, stable; relapses become less frequent and weaker; the total dose of glucocorticoid with PIMT is no more (even less) than required with external corticosteroid therapy; the safety of PIMT is ensured by an acceptable fixed dose of the drug and its reliable natural decrease. Quality of life is improving (service and management are higher): the "ointment dependence" has been eliminated, the procedures are rare, not burdensome; temporary disability is reduced, hospitalization is not required. There is an economic benefit.

Keywords: Psoriasis; Pulse Immunomodulatory Mesotherapy; Mini-Dose of Glucocorticoid; Quality of Life


  1. Albert A. “Selektive toxicity. The physico-chemical basis of therapy”. 7th ed, - Chapman and Hall. - London, N.-Y 1(1985).
  2. Valencia IC and Kerdel FA. “Local corticosteroids”. In: Fitzpatrick’s Dermatology in General Medicine/Wolff K., Goldsmith L.A., Katz S.I., Gilchrest B.A., Paller A.S., Leffell D.J. - McGraw Companies. - N.-Y., Chicago, London., et al., (2008).
  3. Zavadsky VN. “Pulse mesotherapy of immunoassociated dermatoses”. Russian Journal of Skin and Venereal Diseases 5(2014): 31-35.
  4. Krueger GG., et al. “Medical Advisory Board of the National Psoriasis Foundation/A new scoring system to determine if clinically significant improvement has occurred in clinical trials that assess the effect of therapy on psoriasis”. Psoriasis Forum1(2002): 3-4.
  5. Weber E. “Grundriss der biologischen Statistik fűr Naturwissenschaftler, Landwirte und Mediziner. – 4. Auflage.- VEB G.Fischer Verlag, - Jena, (1961): 515-521
  6. Roenigk HH. “Methotrexate in psoriasis: consensus conference”. Journal of the American Academy of Dermatology 38(1998): 478-485.


Citation: Zavadsky VN. “Pulse Immunomodulatory Mesotherapy of Psoriasis”.Acta Scientific Medical Sciences 7.3 (2023): 109-112.


Copyright: © 2022 Zavadsky VN. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

Contact US